The frenzy of deals around IO programs and companies has led to what could be referred to as “BD outpacing science.” That might be said too of the combination trials that have displayed varied results, with a few showing clear benefit, some being outright failures and some promising but not definitive signs of efficacy. These results, while not exactly slowing the IO gold rush, have somewhat tempered enthusiasm and perhaps led to a certain maturing in dealmaking, as seen by the shifting to more back loaded terms. Which is all by way of framing the context of the macroenvironment, which now begs the question of where will the next big shift come from in immunotherapy.
This podcast, recorded at the 2020 IO360° Summit, will tie together discussion on scientific, translational and business development considerations into the latest thinking on strategizing development in IO that will impact collaborations and investment decision making.
Jeffrey Bockman, PhD, Cello Health BioConsulting
Jennifer Buell, PhD, Agenus Bio
Charles Drake, MD, PhD, Columbia University Medical Center
Asthika Goonewardene, MBA, SunTrust Robinson Humphrey
Michael King Jr, Fortress Biotech
Emmett Schmidt, MD, PhD, Merck Research Labs
To learn more about the upcoming 2021 IO360° Summit, please visit www.io360summit.com